Genialis
Private Company
Total funding raised: $19M
Overview
Genialis is a Boston-based precision oncology company founded in 2015, focusing on using AI to de-risk and accelerate oncology drug development. Its core technology is the Genialis Supermodel, a foundation AI model of cancer biology, supported by a multiomics data infrastructure called Genialis Expressions. The company provides therapeutic intelligence across the drug development lifecycle, aiming to improve patient stratification, understand drug mechanisms of action, and increase clinical trial success rates for its biopharma partners.
Technology Platform
Genialis Supermodel (AI foundation model of cancer biology) and Genialis Expressions (multiomics & clinical data infrastructure).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Genialis competes in the crowded AI/ML for drug discovery and precision oncology space, facing competition from pure-play AI biotechs (e.g., Recursion, Exscientia), large tech companies (e.g., Google's Isomorphic Labs), and diagnostic firms building predictive models. Differentiation hinges on the claimed superiority of its 'foundation model' approach and its deep focus on oncology.